Delisting risk
RNTX · NASDAQ · Biotechnology

Rein Therapeutics (RNTX)

Develops peptide candidates for pulmonary fibrosis and related lung diseases.

$0.7997
Pre-market+0.02 (+3.21%)
At close$0.7748(+2.94%)

Something off on this page? Send us feedback.

Next report
Nov 13, 2026
in 71 days
EPS estimate
−$0.10
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Apr '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.26−$0.28−$0.21−$1.09−$0.19−$0.10−$0.10Pending
Estimate−$0.14−$0.22−$0.24−$1.09−$0.49−$0.17−$0.17−$0.10
Surprise−85.7%−27.3%+12.5%0.0%+61.2%+41.2%+41.2%

RevenueReportedEstimate

Apr '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported$0Pending
Estimate
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.10
Aug 2026−$0.17−$0.10+41.2%
Aug 2026−$0.17−$0.10+41.2%
May 2026−$0.49−$0.19+61.2%
Mar 2026−$1.09−$1.090.0%

The latest year is open to everyone — the 12 quarters behind it read with an account.

Sign in
Nov 2025
Aug 2025
Apr 2025
Dec 2024
Nov 2024
Aug 2024
Mar 2024
Dec 2023
Sep 2023
Jun 2023
May 2023−$0.60
Mar 2023−$1.30
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 13, 2026−$0.10
Aug 14, 2026−$0.17−$0.10+41.2%+2.4%
Aug 13, 2026−$0.17−$0.10+41.2%$0−2.2%
May 15, 2026−$0.49−$0.19+61.2%−1.0%
Mar 26, 2026−$1.09−$1.090.0%−1.6%

The latest year is open to everyone — the 12 quarters behind it read with an account.

Sign in
Nov 14, 2025
Aug 14, 2025
Apr 7, 2025
Dec 31, 2024
Nov 14, 2024
Aug 14, 2024
Mar 31, 2024
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
May 8, 2023−$0.60
Mar 20, 2023−$1.30